A Phase 1, Open-Label, Dose-Escalation with Expansion Study of SX-682 in Subjects with Myelodysplastic Syndrome Who Had Disease Progression or are Intolerant to Prior Therapy
Associated ConditionsMyelodysplastic Syndrome
Syntrix Biosystems, Inc
This research study is studying an investigational immunotherapy called SX-682 as a possible treatment for Myelodysplastic Syndrome.
This study is currently enrolling.